Product Labeling Accuracy and Contamination Analysis of Commercially Available Cannabidiol Product Samples

About this resource

This is an English version of a study that purchased cannabidiol (CBD) products sold commercially in the United States and examined whether the amount of CBD on each label matched the analytical value and whether contaminants such as heavy metals, residual solvents, and pesticides were detected. The 202 products included several forms, such as tinctures, gummies, vaping-related products, and topical products. The research question concerned commercial-product quality and labeling reliability, not the clinical effects of CBD itself.

The authors emphasize the need to distinguish pharmaceutical-grade purified CBD from products sold on the general market. Even if a label says CBD, the content, other cannabinoids such as THC, and residues from manufacturing may vary among products. Results from clinical trials therefore cannot be generalized directly to commercial CBD products.

Study design

The research team obtained a range of CBD products through online and retail channels and had them tested by a third-party analytical laboratory. Concentrations of CBD and other cannabinoids were measured and compared with labeled amounts. Label accuracy was classified according to whether the analytical value fell within a specified tolerance around the labeled value. The tests also covered elements including lead, cadmium, arsenic, and mercury, residual solvents potentially arising from manufacturing, and pesticides.

Products were also compared by dosage form. Oral, inhaled, and topical routes differ, and the meaning of exposure is not identical even when the same concentration appears on a label. Detection must also be distinguished from immediate toxicity. Assessing health risk requires concentration, amount used, frequency, regulatory limits, and route of exposure; this study first makes quality discrepancies visible.

The study discloses relationships involving industry-affiliated authors and funding. The conflict-of-interest information needs to be reviewed alongside the transparency of the methods when interpreting the analyses.

Content

The background is the expansion of the CBD market without uniform product labeling and quality control. Less CBD than labeled creates a problem of failing to receive the expected exposure, while more CBD than labeled creates unintended exposure. If THC is present without disclosure, psychoactive effects and consequences for drug testing, driving, or work may occur.

Heavy metals may be taken up by plants from soil or introduced during manufacturing. Residual solvents relate to extraction, while pesticides relate to cultivation practices. Final-product analysis alone cannot establish how contamination occurred, but from a quality-assurance perspective it shows the need to test finished products by lot and make results traceable.

The study makes clear that the label “CBD product” does not denote a chemically uniform category. Marketing terms such as full-spectrum, broad-spectrum, and isolate may not always match measured constituents. A consumer cannot assume from the label alone that a product has the same constituents and purity as a clinical-trial preparation.

Results

The analysis identified products whose CBD content fell outside the labeled amount, including both underlabeling and overlabeling. Patterns of label accuracy varied by dosage form, and not every category had the same quality. Other cannabinoids, including THC, were detected in some products, and in some cases the measured composition did not match the label description.

Testing detected heavy metals, residual solvents, or pesticides in some products. Not every detected value represents the same degree of danger, and the authors also considered relationships with regulatory and toxicological thresholds. The coexistence of several types of discrepancy within the same market nevertheless supports the conclusion that a label at purchase cannot by itself guarantee quality.

The study is not a ranking that recommends particular brands. Nor can products outside the tested sample be judged good or poor. A sample of 202 products shows a broad cross-section, but the market changes continually, and composition may change between lots even within the same brand.

Limitations

Samples were selected from the United States market and do not represent regulation, distribution, or manufacturing quality in other countries. The analysis covered one or a limited number of lots at the time of purchase and cannot show long-term consistency of the same product. It was not a completely random sample of the entire market, and some small businesses and sales channels were not included.

Chemical analysis did not assess how much people actually used or what health effects they experienced. Detection of a contaminant cannot be linked directly to symptoms as causal evidence. Conversely, the absence of measured analytes cannot guarantee a product’s complete safety. Issues outside the testing panel remain, including microorganisms, unknown constituents, migration from containers, and changes during long-term storage.

The study has disclosed industry relationships. This does not automatically invalidate the results, but it is a reason to inspect sample selection, the analytical plan, interpretation, and access to data in the original source. Independent replication is also important.

Safety

Commercial CBD is not identical to pharmaceutical-grade purified CBD. When labeling is inaccurate, exposure is also uncertain when considering drug interactions, somnolence, liver-related concerns, and other effects. Undisclosed THC can lead to unintended psychoactive effects or consequences in drug testing. Because inhaled, oral, and topical products have different routes of exposure, safety cannot be compared from the phrase “a small amount detected” alone.

This page does not provide product-selection, amount, or self-treatment guidance. Even if a label or third-party certificate is present, it does not guarantee total quality unless authenticity, applicable lot, and tested analytes are verified. Pregnancy, breastfeeding, childhood, liver disease, and concurrent medication require safety assessment distinct from a survey of commercial products for the general adult market.

A determination that a value falls within a regulatory limit does not mean harmlessness under every frequency, duration, or combination. When symptoms or drug interactions are suspected, evaluation should use ordinary support pathways such as medical services or poison consultation rather than relying on a product label alone.

Source and rights

Original source: Gidal BE, et al. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Frontiers in Pharmacology. 2024;15:1335441. DOI: 10.3389/fphar.2024.1335441.

The original article is available under Creative Commons Attribution 4.0 (CC BY 4.0). This page is a source-aligned English translation under that license, reconstructed while preserving the argument and section structure. The wording is not literal, and clarifying context has been added to make the analytical targets and limitations explicit. Figures and tables are not reproduced. The original source takes precedence for exact detection rates, analytical methods, regulatory thresholds, and the full conflict-of-interest disclosure.